Also listed under Urinary Bladder Diseases
ClinicalTrials.gov term: Urinary Bladder Neoplasms
Bladder Cancer clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22
What changed in the last 30 days
93 trials changed in the last 30 days: 3 stopped, 39 with notable changes, 51 with minor changes only.
- Notable: Trastuzumab Rezetecan · HER2-Expressiong Advanced Solid Tumor Recruitment opened
- Notable: Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy Recruitment opened
- Notable: IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors Enrollment increased: 260 → 570 participants
- Minor: AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, · Unresectable Locally Advanced or Metastatic Cancer Enrollment closed, study ongoing
- Minor: Bladder EpiCheck European Haematuria Study Enrollment closed, study ongoing
- Minor: Symbiotic-GU-06 · PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer Trial sites expanded: 184 → 198 locations
- Minor: 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2026
- Minor: Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) · Muscle Invasive Bladder Cancer (EV-309) Trial sites expanded: 29 → 37 locations
- Notable: EHR Integrated Remote Patient Monitoring to Reduce Readmission · Bladder Cancer Undergoing Cystectomy Recruitment opened
- Notable: Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors Enrollment increased: 20 → 40 participants
- Minor: Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer · Different Histologies Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations
- Stopped: Tocilizumab, Ipilimumab, and Nivolumab · Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Trial terminated
- Notable: HER3-DXd · Locally Advanced or Metastatic Solid Tumors Primary completion pushed from Sep 1, 2027 to Nov 19, 2030
- Notable: Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Results posted: Nov 17, 2026
- Notable: IAM1363 in HER2 Cancers Primary completion pushed from Dec 2027 to Oct 2028
- Notable: TRAIN · Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer Recruitment opened
- Minor: TroFuse-031 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations
- Minor: Erdafitinib (JNJ-42756493) · Urothelial Cancer Study completion pushed from Mar 31, 2027 to Dec 31, 2027
- Minor: LB-LR1109 · LB-LR1109, Administered Alone · Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC Study completion pushed from Mar 2028 to Dec 2028
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-20 | NCT07951060 LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and… | Kristoffer Rohrberg new | Phase 1/2 |
| 2026-11-20 | NCT07950826 Hybrid Versus Wallace and Bricker Ureteroenteric Anastomosis After Radical Cystectomy… | Başakşehir Çam & Sakura City Hospital new | |
| 2026-11-13 | NCT07936422 A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic… | Centre Leon Berard new | Phase 2 |
| 2026-11-10 | NCT07927400 An Exploratory Study of the Efficacy and Safety of SBRT Following Induction Therapy With… | Tianjin Medical University Cancer Institute and Hospital new | |
| 2026-11-09 | NCT07924046 Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral… | University of Lausanne Hospitals new | |
| 2026-10-27 | NCT07898033 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection… | dmitry enikeev new | Phase 3 |
| 2026-10-26 | NCT07893509 Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and… | Bladder Cancer Advocacy Network new | |
| 2026-10-19 | NCT07881666 Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical… | Hopec Pharma new | Phase 1 |
| 2026-10-06 | NCT07860398 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial… | Optheras AS new | |
| 2026-10-02 | NCT07855926 Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) | LMU Klinikum new |
Active trials by phase
| Early Phase 1 | 14 | |
| Phase 1 | 110 | |
| Phase 1/2 | 87 | |
| Phase 2 | 217 | |
| Phase 2/3 | 15 | |
| Phase 3 | 86 | |
| Phase 4 | 11 |
Not charted: 355 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
National Cancer Institute (NCI) (36) · Memorial Sloan Kettering Cancer Center (20) · Peking University First Hospital (18) · M.D. Anderson Cancer Center (16) · AstraZeneca (15) · Mayo Clinic (13) · Merck Sharp & Dohme LLC (13) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (12) · Janssen Research & Development, LLC (11) · Tianjin Medical University Second Hospital (11)
Get alerts when Bladder Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.